Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?

  • Han, Hye Sook (Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine)
  • Received : 2022.04.15
  • Accepted : 2022.04.23
  • Published : 2022.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  2. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  3. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48. https://doi.org/10.5230/jgc.2019.19.e8
  4. Eom SS, Choi W, Eom BW, Park SH, Kim SJ, Kim YI, et al. A comprehensive and comparative review of global gastric cancer treatment guidelines. J Gastric Cancer 2022;22:3-23. https://doi.org/10.5230/jgc.2022.22.e10
  5. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021;32:368-374. https://doi.org/10.1016/j.annonc.2020.11.017
  6. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019;37:1296-1304. https://doi.org/10.1200/JCO.18.01138
  7. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 2014;40:872-882. https://doi.org/10.1016/j.ctrv.2014.04.004
  8. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177-1188. https://doi.org/10.1056/NEJMoa1713709
  9. Yu Y, Zhang Z, Meng Q, Wang K, Li Q, Ma Y, et al. Efficacy of different number of XELOX or SOX chemotherapy cycles after D2 resection for stage III gastric cancer. J Gastric Cancer 2022;22:e11.
  10. Qu JL, Li X, Qu XJ, Zhu ZT, Zhou LZ, Teng YE, et al. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One 2013;8:e83196. https://doi.org/10.1371/journal.pone.0083196
  11. Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, et al. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer 2021;21:974. https://doi.org/10.1186/s12885-021-08717-4
  12. Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, et al. 5-Fu-based doublet regimen in patients receiving perioperative or postoperative chemotherapy for locally advanced gastric cancer: when to start and how long should the regimen last? Cancer Manag Res 2021;13:147-161. https://doi.org/10.2147/CMAR.S285361
  13. ClinicalTrials.gov. XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2018 [updated 2019 May 31; cited 2022 Apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03399110.
  14. ClinicalTrials.gov. Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2021 [updated 2022 Feb 21; cited 2022 Apr 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04787354.